Trial Profile
Phase 1 , Placebo-Controlled, Dose-Ranging Trial to Determine Safety and Immunogenicity of an Oral Adenoviral-Vector Based Influenza B Vaccine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs VXA BYW-10 (Primary)
- Indications Influenza B virus infections
- Focus Adverse reactions
- Sponsors Vaxart
- 29 May 2018 Status changed from active, no longer recruiting to completed.
- 08 May 2017 Planned End Date changed from 1 May 2017 to 4 Oct 2018.
- 08 May 2017 Planned primary completion date changed from 1 Sep 2016 to 5 Oct 2017.